United Homes Group stock plunges after Nikki Haley, directors resign
Investing.com -- Johnson & Johnson plans to withdraw a device used to treat acid reflux disease from all markets outside the United States, according to a Bloomberg News report on Tuesday.
JNJ shares are up 0.9% in premarket trade Tuesday.
The company will remove the LINX Reflux Management System from international markets starting in March for commercial reasons, not due to any safety or efficacy concerns, Bloomberg reported, citing a letter sent to doctors.
The LINX device is designed for patients suffering from chronic gastroesophageal reflux disease, a condition where stomach contents flow backward into the esophagus.
The system consists of a flexible ring of small magnets that are placed around muscles at the base of the esophagus. These magnets help keep the muscles closed, preventing the reflux of stomach acid into the food pipe.
Johnson & Johnson has not provided specific details about why it made the decision to withdraw the product from international markets while maintaining availability in the U.S.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.